blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1549760

EP1549760 - SAK: MODULATION OF CELLULAR PROLIFERATION FOR TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.11.2009
Database last updated on 07.10.2024
Most recent event   Tooltip30.09.2011Lapse of the patent in a contracting state
New state(s): CY, TR		published on 02.11.2011  [2011/44]
Applicant(s)For all designated states
Rigel Pharmaceuticals, Inc.
240 E. Grand Avenue
South San Francisco, CA 94080 / US
[2005/27]
Inventor(s)01 / DEMO, Susan
999 Pocatello Avenue
Sunnyvale, CA 94087 / US
02 / HITOSHI, Yasumichi
331 Callippe Court
Brisbane, CA 94005 / US
03 / JENKINS, Yonchu
1279 Page Street
San Francisco, CA 94117 / US
 [2005/27]
Representative(s)Manitz Finsterwald Patent- und Rechtsanwaltspartnerschaft mbB
Martin-Greif-Strasse 1
80336 München / DE
[N/P]
Former [2005/27]Manitz, Finsterwald & Partner GbR
Martin-Greif-Strasse 1
80336 München / DE
Application number, filing date02750377.031.07.2002
[2005/27]
WO2002US24312
Priority number, dateUS20010309632P01.08.2001         Original published format: US 309632 P
US2001002602121.12.2001         Original published format: US 26021
[2005/27]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03012055
Date:13.02.2003
Language:EN
[2003/07]
Type: A2 Application without search report 
No.:EP1549760
Date:06.07.2005
Language:EN
The application published by WIPO in one of the EPO official languages on 13.02.2003 takes the place of the publication of the European patent application.
[2005/27]
Type: B1 Patent specification 
No.:EP1549760
Date:31.12.2008
Language:EN
[2009/01]
Search report(s)International search report - published on:US12.05.2005
(Supplementary) European search report - dispatched on:EP09.03.2006
ClassificationIPC:C12Q1/68, C12Q1/48, G01N33/53, A61K39/395, A61K48/00
[2008/26]
CPC:
G01N33/57484 (EP,US); A61K2039/505 (EP,US); A61K38/00 (EP,US);
G01N2333/912 (EP,US)
Former IPC [2005/27]C12Q1/68, C12Q1/48, G01N33/53, A61K39/395, A61K48/00, A61K7/46
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2005/27]
Extension statesAL01.03.2004
LT01.03.2004
LV01.03.2004
MK01.03.2004
RO01.03.2004
SI01.03.2004
TitleGerman:SAK: MODULATION DER ZELLPROLIFERATION ZUR KREBSBEHANDLUNG[2005/27]
English:SAK: MODULATION OF CELLULAR PROLIFERATION FOR TREATMENT OF CANCER[2005/27]
French:PROTEINE KINASE SAK: MODULATION DE LA PROLIFERATION CELLULAIRE DESTINEE AU TRAITEMENT DU CANCER[2005/27]
Entry into regional phase01.03.2004National basic fee paid 
01.03.2004Search fee paid 
01.03.2004Designation fee(s) paid 
01.03.2004Examination fee paid 
Examination procedure28.02.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
01.03.2004Amendment by applicant (claims and/or description)
01.03.2004Examination requested  [2005/27]
11.10.2006Despatch of a communication from the examining division (Time limit: M05)
21.03.2007Reply to a communication from the examining division
14.06.2007Despatch of a communication from the examining division (Time limit: M06)
14.12.2007Reply to a communication from the examining division
30.05.2008Communication of intention to grant the patent
08.10.2008Fee for grant paid
08.10.2008Fee for publishing/printing paid
Opposition(s)01.10.2009No opposition filed within time limit [2009/50]
Fees paidRenewal fee
22.07.2004Renewal fee patent year 03
20.07.2005Renewal fee patent year 04
27.07.2006Renewal fee patent year 05
20.07.2007Renewal fee patent year 06
05.11.2008Renewal fee patent year 07
Penalty fee
Additional fee for renewal fee
31.07.200807   M06   Fee paid on   05.11.2008
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT31.12.2008
CY31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
TR31.12.2008
BG31.03.2009
SE31.03.2009
GR01.04.2009
PT01.06.2009
CH31.07.2009
IE31.07.2009
LI31.07.2009
LU31.07.2009
MC31.07.2009
[2011/43]
Former [2011/21]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
GR01.04.2009
PT01.06.2009
CH31.07.2009
IE31.07.2009
LI31.07.2009
LU31.07.2009
MC31.07.2009
Former [2010/48]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
GR01.04.2009
PT01.06.2009
CH31.07.2009
IE31.07.2009
LI31.07.2009
MC31.07.2009
Former [2010/35]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
PT01.06.2009
CH31.07.2009
IE31.07.2009
LI31.07.2009
MC31.07.2009
Former [2010/21]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
PT01.06.2009
CH31.07.2009
LI31.07.2009
MC31.07.2009
Former [2010/11]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
PT01.06.2009
MC31.07.2009
Former [2010/08]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
BG31.03.2009
SE31.03.2009
PT01.06.2009
Former [2009/46]AT31.12.2008
CZ31.12.2008
DK31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
SE31.03.2009
PT01.06.2009
Former [2009/43]AT31.12.2008
CZ31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SK31.12.2008
SE31.03.2009
PT01.06.2009
Former [2009/39]AT31.12.2008
CZ31.12.2008
EE31.12.2008
FI31.12.2008
NL31.12.2008
SE31.03.2009
PT01.06.2009
Former [2009/38]EE31.12.2008
FI31.12.2008
NL31.12.2008
SE31.03.2009
PT01.06.2009
Former [2009/36]EE31.12.2008
FI31.12.2008
NL31.12.2008
Former [2009/25]FI31.12.2008
NL31.12.2008
Documents cited:Search[X]  - HUDSON J W ET AL, "Late mitotic failure in mice lacking Sak, a polo-like kinase", CURRENT BIOLOGY, (20010320), vol. 11, no. 6, ISSN 0960-9822, pages 441 - 446, XP002369281 [X] 9-50 * abstract *

DOI:   http://dx.doi.org/10.1016/S0960-9822(01)00117-8
 [X]  - FODE CAROL ET AL, "Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation", MOLECULAR AND CELLULAR BIOLOGY, (1996), vol. 16, no. 9, ISSN 0270-7306, pages 4665 - 4672, XP002369282 [X] 9-50 * the whole document *
 [A]  - HUDSON JOHN W ET AL, "Sak kinase gene structure and transcriptional regulation", GENE (AMSTERDAM), (20000104), vol. 241, no. 1, ISSN 0378-1119, pages 65 - 73, XP002369283 [A] 1-50 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0378-1119(99)00467-9
 [A]  - KARN THOMAS ET AL, "Human SAK related to the PLK/polo family of cell cycle kinases shows high mRNA expression in testis", ONCOLOGY REPORTS, (1997), vol. 4, no. 3, ISSN 1021-335X, pages 505 - 510, XP008060542 [A] 1-50 * the whole document *
 [A]  - HIRAO A ET AL, "DNA DAMAGE-INDUCED ACTIVATION OF P53 BY THE CHECKPOINT KINASE CHK2", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, (20000310), vol. 287, ISSN 0036-8075, pages 1824 - 1827, XP002945471 [A] 1-8 * abstract *

DOI:   http://dx.doi.org/10.1126/science.287.5459.1824
 [A]  - LUKAS CLAUDIA ET AL, "DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology", CANCER RESEARCH, (20010701), vol. 61, no. 13, ISSN 0008-5472, pages 4990 - 4993, XP002369284 [A] 1-8 * abstract *
 [PX]  - MACMILLAN J C ET AL, "Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer.", ANNALS OF SURGICAL ONCOLOGY : THE OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY. OCT 2001, (200110), vol. 8, no. 9, ISSN 1068-9265, pages 729 - 740, XP002369285 [PX] 9-50 * the whole document *
International search[X]US5976893  (DENNIS JAMES W [CA], et al);
 [A]US6569662  (TANG Y TOM [US], et al);
 [X]  - FODE ET AL., "Sak, a murine proteine-serine/threonine kinase that is related to the Drosophila polo kinase and involved in cell proliferation", PROC. NATL. ACAD. SCI. USA, USA, (199407), vol. 91, pages 6388 - 6392, XP002984335

DOI:   http://dx.doi.org/10.1073/pnas.91.14.6388
by applicantUS4816567
 US5010175
 WO9119735
 WO9200091
 WO9320242
 US5288514
 US5539083
    - SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
    - NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
    - PEARSON; LIPMAN, PROC. NAT'L. ACAD. SCI. USA, (1988), vol. 85, page 2444
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - PRESTA, CURR OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - FURKA, INT. J. PEPT. PROT. RES., (1991), vol. 37, pages 487 - 493
    - HOUGHTON ET AL., NATURE, (1991), vol. 354, pages 84 - 88
    - HOBBS ET AL., PROC. NAT. ACAD. SCI. USA, (1993), vol. 90, pages 6909 - 6913
    - HAGIHARA ET AL., J. AMER. CHEM. SOC., (1992), vol. 114, page 6568
    - HIRSCHMANN ET AL., J. AMER. CHEM. SOC., (1992), vol. 114, pages 9217 - 9218
    - CHEN ET AL., J. AMER. CHEM. SOC., (1994), vol. 116, page 2661
    - CHO, SCIENCE, (1993), vol. 261, page 1303
    - CAMPBELL ET AL., J. ORG. CHEM., (1994), vol. 59, page 658
    - VAUGHN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, no. 3, pages 309 - 314
    - MERRIFIELD, J. AM. CHEM. SOC., (1963), vol. 85, pages 2149 - 2154
    - GEYSEN ET AL., J IMMUN. METH., (1987), vol. 102, pages 259 - 274
    - FRANK; DORING, TETRAHEDRON, (1988), vol. 44, pages 6031 - 6040
    - FODOR ET AL., SCIENCE, (1991), vol. 251, pages 767 - 777
    - SHELDON ET AL., CLINICAL CHEMISTRY, (1993), vol. 39, no. 4, pages 718 - 719
    - KOZAL ET AL., NATURE MEDICINE, (1996), vol. 2, no. 7, pages 753 - 759
    - KOHLER; MILSTEIN, NATURE, (1975), vol. 256, pages 495 - 497
    - ANDERSON, SCIENCE, (1992), vol. 256, pages 808 - 813
    - NABEL; FELGNER, TIBTECH, (1993), vol. 11, pages 211 - 217
    - MITANI; CASKEY, TIBTECH, (1993), vol. 11, pages 162 - 166
    - MULLIGAN, SCIENCE, (1993), pages 926 - 932
    - DILLON, TIBTECH, (1993), vol. 11, pages 167 - 175
    - MILLER, NATURE, (1992), vol. 357, pages 455 - 460
    - VAN BRUNT, BIOTECHNOLOGY, (1998), vol. 6, no. 10, pages 1149 - 1154
    - VIGNE, RESTORATIVE NEUROLOGY AND NEUROSCIENCE, (1995), vol. 8, pages 35 - 36
    - KREMER; PERRICAUDET, BRITISH MEDICAL BULLETIN, (1995), vol. 51, no. 1, pages 31 - 44
    - HADDADA ET AL., CURRENT TOPICS
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.